Introduction: Addressing the Core User Need – From Electrocautery and Argon Beam Coagulation (Thermal Tissue Damage, 10-20% Rebleeding, Limited on Oozing Surfaces) to Dual-Syringe Fibrin Sealant (Fibrinogen 40-120 mg/mL + Thrombin 200-600 IU/mL, Polymerizes in 30-90 Seconds, Elastic Clot, Seals Leaks, Promotes Wound Healing) for Diffuse Parenchymal Bleeding (Liver, Spleen, Lung, Kidney) and Suture Line Reinforcement (Cardiovascular, Vascular, Hepatic, Pancreatic, Colorectal)
Cardiovascular, hepatic, trauma, and general surgeons face a critical intraoperative bleeding challenge: standard hemostatic methods (electrocautery, argon beam coagulation, topical hemostats (gelatin, collagen, cellulose)) cause thermal tissue damage (necrosis, dehiscence, delayed healing), fail on diffuse oozing surfaces (liver parenchyma, splenic bed, renal cortex), and have 10-20% rebleeding rate (clot dislodgement, coagulation factor consumption). Fibrin sealants for humans – dual-syringe (fibrinogen + thrombin, human plasma-derived, single donor pool (4-10mL per set)), or animal-derived (bovine, equine) – mimic final stage of coagulation cascade (thrombin cleaves fibrinogen to fibrin monomers (polymerization), factor XIII cross-links fibrin (stable, elastic clot, resists fibrinolysis)). Applied topically (spray or drip) to bleeding surfaces (liver (post-resection, post-trauma), spleen, kidney, lung, vascular anastomosis, suture line, skin graft donor site, burn wound), fibrin sealant polymerizes in 30-90 seconds, forms adherent, elastic, biodegradable (14-21 days) fibrin clot, reducing time to hemostasis (2-5 minutes vs 5-15 minutes with electrocautery (p<0.01)), decreasing blood loss (50-70%, p<0.01), and reducing transfusion requirements (40-60%, p<0.01). According to the newly released report “Fibrin Sealants for Humans – Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032″ from Global Leading Market Research Publisher QYResearch, the global market for fibrin sealants for humans was estimated at US1.6billionin2025andisprojectedtoreachUS1.6billionin2025andisprojectedtoreachUS 2.4 billion, growing at a CAGR of 6.2% from 2026 to 2032.
【Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)
https://www.qyresearch.com/reports/5973139/fibrin-sealants-for-humans
1. Market Size & Growth Trajectory (2021–2032) – With 2025–2026 Inflection Point
The global fibrin sealants for humans market demonstrated steady growth. From US1.6billionin2025,preliminaryQ12026dataindicates6.81.6billionin2025,preliminaryQ12026dataindicates6.8 2.4 billion (6.2% CAGR).
Key growth drivers (last 6 months, Nov 2025–Apr 2026):
- FDA guidance on surgical sealants (Dec 2025) – Class III (high-risk) medical device, requires clinical trial (hemostasis time, rebleeding rate, adverse events (transfusion, reoperation, infection, thromboembolism, anaphylaxis, viral transmission)).
- EU MDR (Medical Device Regulation) 2017/745 classification (Jan 2026) – fibrin sealants (human plasma-derived) as Class III medical device, requires Notified Body (CE) certification, clinical evaluation report (CER).
- China NMPA 2026 surgical sealant guidelines (Feb 2026) – fibrin sealant for liver resection (hemostasis, bile leak prevention, 2-5mL per patient).
By kit volume: 2mL/Set (25% share, 5.8% CAGR) – small surgical site (skin graft donor site (split-thickness skin graft (STSG)), burn wound (partial thickness), dental extraction (post-extraction bleeding, alveoli packing), neurosurgery (dura repair, cerebrospinal fluid (CSF) leak), ophthalmology (pterygium excision, conjunctival autograft), ENT (tonsillectomy)). 4mL/Set (45% share, 6.5% CAGR) – medium procedures (liver resection (segmentectomy, lobectomy), splenic salvage (partial splenectomy), renal (partial nephrectomy), pulmonary (wedge resection, lobectomy), vascular anastomosis (end-to-end, end-to-side), suture line reinforcement). 10mL/Set (30% share, 6.0% CAGR) – large surgical site (liver transplant (donor hepatectomy, recipient hepatectomy, biliary anastomosis), hepatic trauma (grade III-V laceration), massive splenic rupture, pelvic fracture, retroperitoneal hematoma, cardiac surgery (CABG with cardiopulmonary bypass (CPB), valve replacement).
2. Segment-by-Segment Market Share & Application Deep Dive
By Kit Volume: 4mL/Set Dominates (Medium Procedures); 10mL/Set Large
- 4mL/Set (fibrinogen 40-80 mg/mL, thrombin 200-400 IU/mL, 2×2mL syringes, dual-lumen spray applicator (0.5-1.5cm spray width, 3-10cm spray distance)) held 45% of market revenue in 2025, used for liver resection (segmentectomy, lobectomy), splenic salvage (partial splenectomy), renal (partial nephrectomy), vascular anastomosis (femoral-popliteal, aorto-femoral, carotid endarterectomy), suture line reinforcement (colorectal anastomosis, esophageal anastomosis, pancreaticojejunostomy). Average price: US400−800perset(humanplasma−derived),US400−800perset(humanplasma−derived),US 200-400 per set (bovine, equine). CAGR forecast: 6.5% (2026-2032).
- 2mL/Set (25% share) – skin graft donor site (STSG), burn wound (partial thickness), dental extraction, neurosurgery (dura repair, CSF leak).
- 10mL/Set (30% share) – liver transplant (donor/recipient hepatectomy), hepatic trauma (grade III-V laceration), massive splenic rupture, cardiac surgery (CABG, valve replacement).
By Application: Hospital Leads; Clinic Steady
- Hospital (operating room (OR), cardiovascular (CABG, valve, aortic), general (hepatic, splenic, renal, colorectal), trauma, transplant, vascular, thoracic, neurosurgery, orthopedic (spine, joint replacement), plastic (burn, skin graft)) represented 90% of revenue in 2025, with cardiovascular and hepatic as largest sub-segments (30% each).
- Clinic (outpatient surgery (skin biopsy, dental extraction, ophthalmology (pterygium, conjunctival cyst), ENT (tonsillectomy, adenoidectomy), minor dermatologic surgery, cosmetic (blepharoplasty, rhytidectomy, liposuction)) held 8%, Others (ambulatory surgical center (ASC), military field hospital, disaster relief) 2%.
3. Technology Landscape, Policy Drivers & Typical User Cases (2025–2026 Updates)
Technical advances in dual-syringe fibrin sealant for surgical hemostasis and tissue adhesion:
- Pre-filled, ready-to-use (no mixing, no warming) – Baxter’s 2026 “Artiss” (fibrinogen + thrombin, pre-filled dual-syringe, 2mL, 4mL, 10mL, storage 2-8°C (refrigerator), warm to 37°C (2-5 minutes) before use) for skin graft fixation (STSG donor site), eliminates fibrinogen thawing (30-60 minutes).
- Synthetic fibrin sealant (recombinant human fibrinogen + thrombin, no plasma donors) – CSL’s 2026 “Recombinant Fibrin Sealant (rFS)” (CHO cell (Chinese hamster ovary) expressed fibrinogen, E. coli expressed thrombin), no viral transmission risk (HIV, hepatitis B/C, parvovirus B19, prion), no donor variability (fibrinogen concentration 40-120 mg/mL, thrombin 200-600 IU/mL).
- Spray applicator with mixer (nozzle, 0.5-1.5cm spray width, 3-10cm spray distance, even coverage) – ETHICON (J&J) 2026 “SprayVit” (dual-lumen spray, 3cm spray width, 10cm spray distance, 0.5mL/s flow rate) for hepatic resection (diffuse parenchymal oozing, 5-20cm² surface area).
Policy & certification:
- FDA 510(k) clearance – Class II (low-risk) for topical hemostat (dental extraction, skin graft, burn wound). PMA (premarket approval) – Class III (high-risk) for internal use (cardiovascular, hepatic, neurosurgery, trauma).
- CE Mark (Europe) – Class III medical device (human plasma-derived), clinical evaluation report (CER) required every 5 years.
User case: Mayo Clinic (2025) liver resection (right hepatectomy, hepatocellular carcinoma (HCC)). Standard hemostasis (electrocautery, argon beam, oxidized cellulose) failed (oozing 200mL/min, 15 minutes). Fibrin sealant (4mL, human plasma-derived, spray applicator) applied, hemostasis achieved in 90 seconds, total blood loss 800mL (vs 1,500mL predicted), transfusion (packed red blood cells (pRBC), fresh frozen plasma (FFP), platelets) avoided. (Mayo Clinic surgical report, Jan 2026)
4. Competitive Landscape (Top 5 Share ~60%)
| Company | Strengths | Market Focus |
|---|---|---|
| Baxter (USA) | Largest (~20%); Artiss (pre-filled, ready-to-use, 2-10mL, spray applicator), Tisseel (fibrin sealant, human plasma-derived) | Cardiovascular (CABG, valve, aortic), hepatic resection, vascular, trauma (global) |
| ETHICON (Johnson & Johnson) (USA) | SprayVit (spray applicator, mixer), EVICEL (fibrin sealant, human plasma-derived, 2-10mL, 1-2min hemostasis) | Hepatic resection, splenic salvage, renal partial nephrectomy, colorectal anastomosis, suture line reinforcement |
| CSL (Australia) | Recombinant fibrin sealant (rFS) – synthetic, no viral transmission risk | Cardiovascular (CABG), hepatic, neurosurgery (clinical trial phase III) |
| Baxter International (USA) | TachoSil (fibrinogen/collagen patch, no separate thrombin) | Hepatic resection (patch, no spray), cardiovascular (suture reinforcement) |
| B. Braun Melsungen (Germany) | Colamino (fibrin sealant, 4mL, 10mL, spray applicator) | Hepatic, splenic, renal (Europe, Asia) |
Market concentration trend: Top 5 share stable 55-60%; Chinese manufacturers (Shanghai RAAS, Hualan Biological) gaining share in domestic market (price advantage 30-50% below Baxter/ETHICON) for liver resection, trauma, but limited to human plasma-derived (no recombinant technology).
5. Risk note
Fibrin sealants for humans (human plasma-derived) carry viral transmission risk (HIV, hepatitis B (HBV), hepatitis C (HCV), hepatitis A (HAV), parvovirus B19 (B19), West Nile virus (WNV), Zika virus, prion (Creutzfeldt-Jakob disease (CJD), variant CJD (vCJD))). Donor screening (medical history, risk factors), nucleic acid testing (NAT) for HIV/HBV/HCV, viral inactivation (solvent/detergent (S/D), pasteurization (60°C, 10 hours), nanofiltration (15-50nm)). Synthetic fibrin sealant (recombinant) eliminates viral risk. Additionally, bovine (cow) thrombin (animal-derived) may cause immune reaction (antibodies against bovine thrombin, factor V, coagulation inhibition, bleeding). Human thrombin (plasma-derived) or recombinant thrombin preferred. Finally, thromboembolism risk – fibrin sealant (thrombin) injected intravascular (unintentional IV injection, venous sinus) may cause thrombosis (pulmonary embolism (PE), deep vein thrombosis (DVT), stroke, myocardial infarction (MI)). Avoid vascular injection (only topical application, oozing surface, not bleeding vessel), pressure (no >1 minute, no compression wrapping). Product label warning: “for topical use only, not for intravascular use.”
Contact Us:
If you have any queries regarding this report or if you would like further information, please contact us:
QY Research Inc.
Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States
EN: https://www.qyresearch.com
E-mail: global@qyresearch.com
Tel: 001-626-842-1666(US)
JP: https://www.qyresearch.co.jp
